Quarterly report · Q2
6523.TEDINET S100S7VD
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥166.8bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥85.5bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥356.4bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥170.6bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥89.1bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥4.2bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥2.5bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥10.5bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥8.5bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥3.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥557m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥179m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥9.7bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥2.5bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥743m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥3.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥8.3bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥2.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥733m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥8.5bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥570.4bn | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥561.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥596.3bn | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥423.4bn | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥422.7bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥147.0bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥138.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥149.3bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥136.1bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥147.4bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥138.0bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥148.3bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥61.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥73.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥95.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥22.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥21.4bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥5.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥17.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥8.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥23.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥40.8bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥20.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-19.55 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥5.91 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-25.84 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥9.61 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥66.6 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-19.55 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥5.88 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-25.84 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥9.52 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥65.98 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 25.8% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.6% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.9% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥4.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥52.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥52.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥4.7bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥51.1bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥51.1bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥61.8bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥61.8bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.7bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥165.7bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥165.7bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥8.9bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥9.4bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥55.4bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥55.4bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥12.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥49.3bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥49.3bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥64.8bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥64.8bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥5.3bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥169.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥169.5bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥20.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 914
| Item | Context | Value | Unit |
|---|---|---|---|
| Equity IFRS | CurrentQuarterInstant | 147042000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 3395000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | -3030000000 | JPY |
| Depreciation expense ope cf IFRS | Prior1YTDDuration | 14809000000 | JPY |
| Depreciation expense ope cf IFRS | CurrentYTDDuration | 13383000000 | JPY |
| Impairment losses reversal of impairment losses ope cf IFRS | Prior1YTDDuration | 257000000 | JPY |
| Impairment losses reversal of impairment losses ope cf IFRS | CurrentYTDDuration | 2118000000 | JPY |
| Gain loss from financial assets measured at fair value through profit or loss ope cf IFRS | Prior1YTDDuration | 2944000000 | JPY |
| Gain loss from financial assets measured at fair value through profit or loss ope cf IFRS | CurrentYTDDuration | -247000000 | JPY |
| Interest expenses ope cf IFRS | Prior1YTDDuration | 3217000000 | JPY |
| Interest expenses ope cf IFRS | CurrentYTDDuration | 3783000000 | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | Prior1YTDDuration | 265000000 | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | CurrentYTDDuration | 138000000 | JPY |
| Loss gain on sale of fixed assets ope cf IFRS | Prior1YTDDuration | -8000000 | JPY |
| Loss gain on sale of fixed assets ope cf IFRS | CurrentYTDDuration | -26000000 | JPY |
| Decrease increase in trade receivables ope cf IFRS | Prior1YTDDuration | 6012000000 | JPY |
| Decrease increase in trade receivables ope cf IFRS | CurrentYTDDuration | 8785000000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -4059000000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | -2959000000 | JPY |
| Increase decrease in trade payables ope cf IFRS | Prior1YTDDuration | -6794000000 | JPY |
| Increase decrease in trade payables ope cf IFRS | CurrentYTDDuration | -2614000000 | JPY |
| Increase decrease in retirement benefit liability ope cf IFRS | Prior1YTDDuration | 53000000 | JPY |
| Increase decrease in retirement benefit liability ope cf IFRS | CurrentYTDDuration | -115000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | -4665000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | 3096000000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 15429000000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 22309000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 267000000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 496000000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -1836000000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -3290000000 | JPY |
| Income taxes paid ope cf IFRS | Prior1YTDDuration | -8771000000 | JPY |
| Income taxes paid ope cf IFRS | CurrentYTDDuration | -3267000000 | JPY |
| Income taxes refund ope cf IFRS | Prior1YTDDuration | 366000000 | JPY |
| Income taxes refund ope cf IFRS | CurrentYTDDuration | 6429000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 5455000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 22677000000 | JPY |
| Purchase of property plant and equipment and intangible assets inv cf IFRS | Prior1YTDDuration | -5677000000 | JPY |
| Purchase of property plant and equipment and intangible assets inv cf IFRS | CurrentYTDDuration | -6921000000 | JPY |
| Proceeds from sale of property plant and equipment and intangible assets inv cf IFRS | Prior1YTDDuration | 63000000 | JPY |
| Proceeds from sale of property plant and equipment and intangible assets inv cf IFRS | CurrentYTDDuration | 265000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YTDDuration | -1798000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYTDDuration | － | JPY |
| Proceeds from sale of investments accounted for using equity method inv cf IFRS | Prior1YTDDuration | － | JPY |
| Proceeds from sale of investments accounted for using equity method inv cf IFRS | CurrentYTDDuration | 3703000000 | JPY |
| Purchase of investments inv cf IFRS | Prior1YTDDuration | -290000000 | JPY |
| Purchase of investments inv cf IFRS | CurrentYTDDuration | － | JPY |
| Other inv cf IFRS | Prior1YTDDuration | -723000000 | JPY |
| Other inv cf IFRS | CurrentYTDDuration | 828000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -8425000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |